DPH — Dechra Pharmaceuticals Share Price
Last trade - 00:00- £4.40bn
- £4.83bn
- £761.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.07 | ||
| PEG Ratio (f) | 0.91 | ||
| EPS Growth (f) | 44.29% | ||
| Dividend Yield (f) | 1.31% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.83 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 132.17 | ||
| Price to Sales | 5.78 | ||
| EV to EBITDA | 34.81 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.07% | ||
| Return on Equity | -3.92% | ||
| Operating Margin | -1.98% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 481.8 | 515.1 | 608 | 681.8 | 761.5 | 835.14 | 915.04 | 13.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.43 | -2.15 | +24.05 | +32.12 | -40.04 | +121.88 | +14.46 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company’s segments include European Pharmaceuticals, NA Pharmaceuticals, and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment comprises of Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing & Supply. This Segment operates internationally and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Dechra Veterinary Products Canada, and Dechra Productos Veterinarios (Mexico), which sell CAP, Equine and FAP in those territories. The Segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas. The Pharmaceuticals Research and Development Segment includes all of the Company's pharmaceutical research and development activities.
Directors
- Alison Platt CHM
- Ian Page CEO
- Paul Sandland CFO
- Mike Eldred CEX
- Anthony Griffin MDR
- Katy Clough DHR
- Giles Coley OTH (59)
- Anthony Lucas OTH
- Milton McCann OTH
- Allen Mellor OTH
- Melanie Hall SEC
- Lisa Bright NID (53)
- Julian Heslop NID (66)
- Lawson Macartney NID (63)
- Ishbel Macpherson NID (60)
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- May 13th, 1997
- Public Since
- September 21st, 2000
- No. of Employees
- 2,335
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 113,905,890
- Address
- 24 Cheshire Avenue, NORTHWICH, CW9 7UA
- Web
- https://www.dechra.com/
- Phone
- +44 1606814730
- Contact
- Ian Page
- Auditors
- PricewaterhouseCoopers LLP
Latest News for DPH
Upcoming Events for DPH
Half Year 2024 Dechra Pharmaceuticals PLC Earnings Release
Similar to DPH
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 18:06 UTC, shares in Dechra Pharmaceuticals are trading at 3,864.00p. This share price information is delayed by 15 minutes.
Shares in Dechra Pharmaceuticals last closed at 3,864.00p and the price had moved by +36.73% over the past 365 days. In terms of relative price strength the Dechra Pharmaceuticals share price has outperformed the FTSE All Share Index by +40.86% over the past year.
The overall consensus recommendation for Dechra Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDechra Pharmaceuticals does not currently pay a dividend.
Dechra Pharmaceuticals does not currently pay a dividend.
Dechra Pharmaceuticals does not currently pay a dividend.
To buy shares in Dechra Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3,864.00p, shares in Dechra Pharmaceuticals had a market capitalisation of £4.40bn.
Here are the trading details for Dechra Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DPH
Based on an overall assessment of its quality, value and momentum Dechra Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dechra Pharmaceuticals is 4,117.14p. That is 6.55% above the last closing price of 3,864.00p.
Analysts covering Dechra Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of £1.28 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dechra Pharmaceuticals. Over the past six months, its share price has outperformed the FTSE All Share Index by +1.29%.
As of the last closing price of 3,864.00p, shares in Dechra Pharmaceuticals were trading +4.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dechra Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 28.07. The shares last closed at 3,864.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dechra Pharmaceuticals' management team is headed by:
- Alison Platt - CHM
- Ian Page - CEO
- Paul Sandland - CFO
- Mike Eldred - CEX
- Anthony Griffin - MDR
- Katy Clough - DHR
- Giles Coley - OTH
- Anthony Lucas - OTH
- Milton McCann - OTH
- Allen Mellor - OTH
- Melanie Hall - SEC
- Lisa Bright - NID
- Julian Heslop - NID
- Lawson Macartney - NID
- Ishbel Macpherson - NID